Advanced Kidney Cancer: A Guide to Targeted Agents and Immunotherapies

CME Available: https://auau.auanet.org/node/37329

Host: Jay D. Raman, MD, FACS

Co-Hosts: Monika Joshi, MD, MBBS and Brian Matthew Shuch, MD

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to

1. Discuss the current targeted and immunotherapy options available for the treatment of RCC.

2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.

3. Describe best practices in RCC patient selection for treatment options.

4. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients.

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

Sanofi Genzyme